帕唑帕尼治疗药物监测在真实世界软组织肉瘤队列中的临床影响与可行性评估
本研究在122例软组织肉瘤患者中比较TDM指导组(n=95)与非TDM指导组(n=27),评估帕唑帕尼TDM对生存结局和剂量限制性毒性的影响及可行性。两组平均暴露量均为30.5 mg/L,中位PFS和OS无显著差异,TDM组剂量限制性毒性略少,低暴露患者比例较历史数据减半,但TDM对达到目标谷浓度≥20.5 mg/L以改善生存的附加价值未能确认。
要点
- TDM使帕唑帕尼低暴露患者比例从历史26.7%降至13.3%,约减半
- TDM指导组与非TDM指导组中位PFS和OS无显著差异
- TDM指导组剂量限制性毒性发生率44%,非TDM指导组54%
核心结论
- TDM使帕唑帕尼低暴露患者比例约减半,但未能确认其改善软组织肉瘤患者生存的附加价值。
研究设计与样本
- 真实世界队列研究,比较TDM指导组(n=95)与非TDM指导组(n=27),共纳入122例软组织肉瘤患者。
主要发现
- 总体人群平均暴露量为30.5 mg/L,两组相似。
- TDM指导组与非TDM指导组中位PFS分别为5.5个月与4.4个月(p=0.3),中位OS分别为12.6个月与10.1个月(p=0.8)。
- 非TDM指导组剂量限制性毒性发生率为54%,TDM指导组为44%。
- TDM组低暴露患者比例为13.3%,较历史数据26.7%减半。
关键数值与推荐
- 帕唑帕尼目标谷浓度≥20.5 mg/L与延长无进展生存相关。
- 低暴露患者比例:TDM组13.3%,历史数据26.7%。
临床怎么用
- 在软组织肉瘤患者中,TDM可减少低暴露比例,但本研究中未显示生存获益,临床决策需综合考量。
局限性
- 非TDM指导组样本量较小(n=27),可能影响统计效能。
- 可行性评估基于与历史数据的比较,非随机对照设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION AND OBJECTIVE: Pazopanib is registered for metastatic renal cell carcinoma and soft-tissue sarcoma (STS). Its variable pharmacokinetic (PK) characteristics and narrow therapeutic range provide a strong rationale for therapeutic drug monitoring (TDM). Prior studies have defined target levels of drug exposure (≥ 20.5 mg/L) linked to prolonged progression-free survival (PFS), but the added value of using TDM remains unclear. This study investigates the effect of TDM of pazopanib in patients with STS on survival outcomes and dose-limiting toxicities (DLTs) and evaluates the feasibility of TDM-guided dosing. METHODS: A TDM-guided cohort was compared to a non-TDM-guided cohort for PFS, overall survival (OS) and DLTs. PK samples were available from all patients, though not acted upon in the non-TDM-guided cohort. We evaluated the feasibility of TDM by comparing the proportion of underdosed patients in our TDM cohort with data from previous publications. RESULTS: A total of 122 STS patients were included in the TDM-guided cohort (n = 95) and non-TDM-guided cohort (n = 27). The average exposure in the overall population was 30.5 mg/L and was similar in both groups. Median PFS and OS did not differ between the TDM-guided cohort and non-TDM-guided cohort (respectively 5.5 vs 4.4 months, p = 0.3, and 12.6 vs 10.1 months, p = 0.8). Slightly more patients in the non-TDM-guided cohort experienced DLTs (54%) compared to the TDM-guided cohort (44%). The proportion of underdosed patients (13.3%) was halved compared to historical data (26.7%). CONCLUSION: TDM reduced the proportion of patients with subtherapeutic exposure levels by ~ 50%. Nonetheless, the added value of TDM for achieving target trough levels of ≥ 20.5 mg/L for pazopanib on survival outcomes could not be confirmed in STS patients.
引用
- Meertens M, Giraud EL, van der Kleij MBA, et al. Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort. Clin Pharmacokinet. 2024. PMID: 39012619. doi:10.1007/s40262-024-01399-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。